Actively Recruiting
Open Label Study of Combogesic4 IV for Acute Pain Treatment in Children and Adolescents
Led by AFT Pharmaceuticals, Ltd. · Updated on 2026-09-16
60
Participants Needed
4
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how Combogesic4 IV, a combination of ibuprofen and acetaminophen given intravenously, is processed and cleared by the body in children and adolescents aged 2 to under 17 years. The study also aims to assess the safety of this treatment for acute pain in this pediatric population. This phase 3 clinical trial focuses on treatment and is sponsored by AFT Pharmaceuticals, Ltd. Participants will receive Combogesic4 IV by intravenous infusion over 15 minutes every 6 hours as needed, with up to 4 doses in 24 hours. Treatment duration ranges from a minimum of 12 hours 2 doses up to a maximum of 5 days 20 doses depending on body weight. If pain is not adequately controlled, opioids may be added as supplementary medication. Blood samples will be collected before and at specific times after dosing to measure drug levels and to conduct safety assessments including blood and urine tests. During the study, participants will be monitored for adverse events from the start of treatment through 7 days after the last dose. They will also evaluate the study drug at the end of treatment. Researchers will track many safety and pharmacokinetic parameters including heart rate, blood pressure, blood chemistry, hematology values, and opioid use. Participants will stay at the study site for at least 12 hours during treatment and return for a follow-up visit about one week after their last dose. The total participation time is up to 12 days including follow-up.
CONDITIONS
Brief Title
A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain
Research Team
L
Laura Boddington
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here